Laboratorio de Genética Molecular, Servicio de Bioquímica, Hospital de Cruces, 48903 Barakaldo-Bizkaia, Spain.
Fam Cancer. 2009;8(4):533-9. doi: 10.1007/s10689-009-9283-3.
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome underlies between 2 and 5% of all colorectal cancer. It is inherited as an autosomal dominant condition due to mutations in the mismatch repair genes. Fifty-four non-related index cases, 21 of them fulfilling Amsterdam criteria I or II, were studied. Ten (10/21 = 47.6%) different pathological mutations were found in this group, two of which had not previously been reported--one in MLH1 and the other in MSH2-. In the remaining patients, we also found another family with one of these new mutations, and four additional changes, two of which were also new--a pathological change in MSH2 and a second change of uncertain significance in MLH1-, while the other two changes had already been reported. Of all mutations, eight were found in MSH2 (8/15 = 53.3%) and seven in MLH1 (7/15 = 46.6%), suggesting a slightly greater involvement of MSH2 in HNPCC than MLH1 in our population, in contrast to the results reported by other authors.
遗传性非息肉病性结直肠癌(HNPCC)或林奇综合征占所有结直肠癌的 2%至 5%。由于错配修复基因的突变,它作为常染色体显性遗传疾病遗传。研究了 54 名非相关的索引病例,其中 21 名符合阿姆斯特丹标准 I 或 II。在这一组中发现了 10 种(10/21=47.6%)不同的病理突变,其中两种以前没有报道过——一种在 MLH1 中,另一种在 MSH2-中。在其余患者中,我们还发现了另一个携带其中一种新突变的家族,以及另外四种变化,其中两种也是新的——MSH2 中的病理性变化和 MLH1 中的第二个意义不明的变化,而另外两种变化已经有报道。所有突变中,8 种发生在 MSH2(8/15=53.3%),7 种发生在 MLH1(7/15=46.6%),这表明在我们的人群中,MSH2 比 MLH1 更多地参与了 HNPCC,与其他作者的报告结果相反。